Subscribe to our newsletter and never miss the lastest updates.
EraCal closed oversubscribed seed round
16. October 2019
EraCal joins forces with Bernina BioInvest, Redalpine, Life Sciences Fund and private investors to bring first-in-class medicines to patients. We are very grateful for their support of EraCal’s innovative research strategy! This seed investment enables the preclinical development of Era-107, our lead appetite suppressor with remarkable in vivo potency and selectivity, and a platform expansion to new indications.
EraCal wins MIT life science angels award
28. August 2019
EraCal won the MIT life science angels award and enjoyed thrilling days in Boston. Thank you for recognizing our creative science strategy and our global mission!
EraCal received first investment
1. June 2019
The Life Sciences Fund (50% Novartis Venture Fund, 50% UZH Foundation) kicks of EraCal’s lead optimization program. Thank you for joining us on this important mission!